Nozaki T, Sakamoto I, Kagami K, Amemiya K, Hirotsu Y, Mochizuki H
J Gynecol Oncol. 2024; 35(4):e55.
PMID: 38330378
PMC: 11262903.
DOI: 10.3802/jgo.2024.35.e55.
Ghoula M, Kongmeneck A, Eid R, Camproux A, Moroy G
J Phys Chem B. 2023; 127(40):8586-8602.
PMID: 37775095
PMC: 10578311.
DOI: 10.1021/acs.jpcb.3c01467.
Jeong S, Kim J, Lee S, Cho E, Hyun J, Song W
Viruses. 2023; 15(4).
PMID: 37112852
PMC: 10142693.
DOI: 10.3390/v15040873.
Hirotsu Y, Kakizaki Y, Saito A, Tsutsui T, Hanawa S, Yamaki H
Commun Med (Lond). 2023; 3(1):32.
PMID: 36841870
PMC: 9959956.
DOI: 10.1038/s43856-023-00261-5.
Yakoubi A, Dhafer C
Plasmonics. 2023; 18(1):311-347.
PMID: 36588744
PMC: 9786532.
DOI: 10.1007/s11468-022-01754-0.
Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19.
Valenzuela-Fernandez A, Cabrera-Rodriguez R, Ciuffreda L, Perez-Yanes S, Estevez-Herrera J, Gonzalez-Montelongo R
Front Bioeng Biotechnol. 2022; 10:1052436.
PMID: 36507266
PMC: 9732709.
DOI: 10.3389/fbioe.2022.1052436.
Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor-binding affinity.
Hsu Y, Frank M, Mukherjee D, Shchurik V, Makarov A, Mann B
Glycobiology. 2022; 33(2):126-137.
PMID: 36370046
PMC: 9990995.
DOI: 10.1093/glycob/cwac077.
Multiple partition Markov model for B.1.1.7, B.1.351, B.1.617.2, and P.1 variants of SARS-CoV 2 virus.
Garcia J, Gonzalez-Lopez V, Tasca G
Comput Stat. 2022; :1-37.
PMID: 36338539
PMC: 9628379.
DOI: 10.1007/s00180-022-01291-8.
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19.
Liang H, Wu Y, Yau V, Yin H, Lowe S, Bentley R
Vaccines (Basel). 2022; 10(9).
PMID: 36146616
PMC: 9504858.
DOI: 10.3390/vaccines10091538.
STANDARD M10 SARS-CoV-2 Assay for Rapid Detection of SARS-CoV-2: Comparison of Four Real-Time PCR Assays.
Jeong S, Lee N, Lee S, Cho E, Hyun J, Park M
Diagnostics (Basel). 2022; 12(8).
PMID: 36010348
PMC: 9406901.
DOI: 10.3390/diagnostics12081998.
Clinical Performance of Rapid and Point-of-Care Antigen Tests for SARS-CoV-2 Variants of Concern: A Living Systematic Review and Meta-Analysis.
Kim J, Sung H, Lee H, Kim J, Shin S, Jeong S
Viruses. 2022; 14(7).
PMID: 35891461
PMC: 9324571.
DOI: 10.3390/v14071479.
Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data.
Hirotsu Y, Maejima M, Shibusawa M, Natori Y, Nagakubo Y, Hosaka K
Int J Infect Dis. 2022; 122:486-491.
PMID: 35760380
PMC: 9233878.
DOI: 10.1016/j.ijid.2022.06.039.
The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape.
Souza P, Mesquita F, Amaral J, Landim P, Lima K, Costa M
Int J Biol Macromol. 2022; 208:105-125.
PMID: 35300999
PMC: 8920968.
DOI: 10.1016/j.ijbiomac.2022.03.058.
Population Genomics Approaches for Genetic Characterization of SARS-CoV-2 Lineages.
Mostefai F, Gamache I, NGuessan A, Pelletier J, Huang J, Murall C
Front Med (Lausanne). 2022; 9:826746.
PMID: 35265640
PMC: 8899026.
DOI: 10.3389/fmed.2022.826746.
Direct comparison of Xpert Xpress, FilmArray Respiratory Panel, Lumipulse antigen test, and RT-qPCR in 165 nasopharyngeal swabs.
Hirotsu Y, Maejima M, Shibusawa M, Natori Y, Nagakubo Y, Hosaka K
BMC Infect Dis. 2022; 22(1):221.
PMID: 35246055
PMC: 8894560.
DOI: 10.1186/s12879-022-07185-w.
An engineered bispecific human monoclonal antibody against SARS-CoV-2.
Li Z, Li S, Zhang G, Peng W, Chang Z, Zhang X
Nat Immunol. 2022; 23(3):423-430.
PMID: 35228696
DOI: 10.1038/s41590-022-01138-w.
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines.
Jiang Y, Wu Q, Song P, You C
Front Med (Lausanne). 2022; 8:806641.
PMID: 35118097
PMC: 8804231.
DOI: 10.3389/fmed.2021.806641.
The ins and outs of SARS-CoV-2 variants of concern (VOCs).
Salehi-Vaziri M, Fazlalipour M, Khorrami S, Azadmanesh K, Pouriayevali M, Jalali T
Arch Virol. 2022; 167(2):327-344.
PMID: 35089389
PMC: 8795292.
DOI: 10.1007/s00705-022-05365-2.
Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V, Preziusi F, Laera L, Onofrio A, Mercurio I, Todisco S
EPMA J. 2022; 13(1):149-175.
PMID: 35013687
PMC: 8732965.
DOI: 10.1007/s13167-021-00267-w.
Computational modelling of potentially emerging SARS-CoV-2 spike protein RBDs mutations with higher binding affinity towards ACE2: A structural modelling study.
Khan A, Hussain S, Ahmad S, Suleman M, Bukhari I, Khan T
Comput Biol Med. 2022; 141:105163.
PMID: 34979405
PMC: 8716154.
DOI: 10.1016/j.compbiomed.2021.105163.
